Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company focused on discovering and developing antiviral therapeutics for serious and chronic viral diseases. Its programs use structure-based drug design to advance small-molecule candidates for influenza, coronavirus, norovirus, and hepatitis C, but the company does not yet have approved products or recurring product revenue.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaSmall-molecule drug candidates in preclinical and clinical development for viral diseases.
Structure-based technologies used to identify and optimize novel antiviral compounds.
Out-licensing or strategic collaboration potential for programs after early clinical work.
Asiakkaat
Cocrystal does not sell commercial products today; its economic counterparties are primarily investors, clinical research organizations, and potential pharmaceutical partners. If its programs succeed, future customers would likely be pharmaceutical licensees, distributors, and healthcare systems that adopt approved antiviral therapies.
Provide capital through public and private offerings to fund R&D and operations.
May license or co-develop antiviral candidates after clinical de-risking.
Buy trial management and development services to execute studies efficiently.
Hospitals, physicians, and payers would buy approved antivirals if programs reach market.
Strategia
Cocrystal’s strategy is to advance a focused antiviral pipeline through early clinical proof-of-concept while preserving cash through disciplined R&D spending. The company also seeks strategic partners for programs such as CC-31244 and relies on equity financing and the ATM facility to fund development until it can create licensing or commercialization value.
Clinical data are needed to validate efficacy, safety, and partnering value.
Partnerships can provide non-dilutive funding and external development capability.
The company has no ongoing product revenue and depends on external financing.
Maantiede
The company is headquartered in the United States and appears to run a U.S.-centric corporate and financing model, with clinical development activity that can extend into international trial sites and regulatory processes. The 10-Q references the MHRA, indicating at least some clinical or regulatory interaction in the United Kingdom, but no country-level revenue disclosure is provided because the company has no commercial sales.
Riskit
The company faces substantial going-concern and financing risk because it has no approved products, no recurring revenue, and limited cash relative to planned R&D spending. Clinical development risk is also high: trial design, infection rates, regulatory approvals, and candidate safety can all delay or derail programs, while inflation and tariff-related cost pressure could further strain working capital.
The company states its cash is not expected to support working capital needs for 12 months.
Kohdistuu: Corporate funding and ongoing R&D operations
The influenza Phase 2a study faced low infection rates, limiting data analysis.
Kohdistuu: CC-42344 and other pipeline programs
Future funding is expected to come from equity or partner transactions that may dilute holders.
Kohdistuu: ATM facility and future capital raises
Protocol amendments or resubmissions may be needed before additional enrollment can proceed.
Kohdistuu: MHRA-related study actions and clinical timelines
Higher operating and trial costs could stress limited working capital.
Kohdistuu: R&D and general corporate spending
Kirjanpito
Harkinnanvaraiset erätTrial activity, lab services, and employee costs are expensed as incurred and move with program timing.
Vaikutus: Drives quarterly loss volatility and reflects pipeline progress
Management concludes cash may not fund operations for 12 months, requiring explicit disclosure.
Vaikutus: Important for liquidity analysis and valuation
Previously outstanding warrants were accounted for as liabilities and expired in the prior period.
Vaikutus: Can create non-cash fair value changes in earnings
Clinical-stage companies rely on judgment for accruals, contingencies, and valuation inputs.
Vaikutus: Can materially affect reported expenses and balance-sheet items
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Co-Diagnostics, Inc.
CODX · Surgical & Medical Instruments & Apparatus
Vaxcyte, Inc.
PCVX · Biological Products, (No Diagnostic Substances)
Vir Biotechnology, Inc.
VIR · Biological Products, (No Diagnostic Substances)
ProQR Therapeutics N.V.
PRQR · Pharmaceutical Preparations
Trevi Therapeutics, Inc.
TRVI · Pharmaceutical Preparations
Enanta Pharmaceuticals, Inc
ENTA · Pharmaceutical Preparations
Enanta Pharmaceuticals is a U.S.-based biotechnology company focused on discovering and developing small-molecule drugs in virology and immunology.
Päivitetty: 28.4.2026